Curis, Inc. (CRIS) |
|
0.7928 -0.007 (-0.9%)
|
12-05 12:41 |
|
Open: |
0.785 |
Pre. Close: |
0.8 |
|
High:
|
0.807 |
Low:
|
0.78 |
|
Volume:
|
297,415 |
Market Cap:
|
76(M) |
|
|
|
Technical analysis |
as of: 2022-12-05 12:17:55 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.98 One year: 1.08 |
| Support: |
Support1: 0.7 Support2: 0.59 |
| Resistance: |
Resistance1: 0.84 Resistance2: 0.93 |
| Pivot: |
0.83 |
| Moving Average: |
MA(5): 0.79 MA(20): 0.82 
MA(100): 0.9 MA(250): 1.73 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 21.6 %D(3): 29.4 |
| RSI: |
RSI(14): 45.2 |
| 52-week: |
High: 5.26 Low: 0.68 |
| Average Vol(K): |
3-Month: 676 (K) 10-Days: 346 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CRIS ] has closed above bottom band by 19.6%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.82 - 0.83 |
0.83 - 0.83 |
|
Low:
|
0.75 - 0.76 |
0.76 - 0.77 |
|
Close:
|
0.79 - 0.8 |
0.8 - 0.81 |
|
Company Description |
|
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. |
Headline News |
Mon, 05 Dec 2022
Cris Cyborg vs. Gabrielle Holloway: Date, start time, TV channel and live stream - dazn.com
Sun, 04 Dec 2022
NFL World Reacts To Cris Collinsworth's Performance Tonight - The Spun
Sun, 04 Dec 2022
Larissa Pacheco open to future ‘superfights’ including Cris Cyborg, fires back at Aspen Ladd - MMA Fighting
Sat, 03 Dec 2022
Jeopardy! Super-Champ Cris Pannullo Wins 20 Consecutive Games | J!Buzz - Jeopardy!
Tue, 29 Nov 2022
Cris Carter Believes Justin Jefferson Will Be the Greatest Vikings Receiver Ever - Sports Illustrated
Tue, 29 Nov 2022
Donn Davis - Kayla Harrison loss makes fight vs. Cris Cyborg likely - ESPN
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
96 (M) |
| Shares Float |
83 (M) |
|
% Held by Insiders
|
5.9 (%) |
|
% Held by Institutions
|
40 (%) |
|
Shares Short
|
3,640 (K) |
|
Shares Short P.Month
|
4,150 (K) |
Stock Financials |
|
EPS
|
-0.57 |
|
EPS Est Next Qtl
|
-0.1 |
|
EPS Est This Year
|
-0.39 |
|
EPS Est Next Year
|
-0.39 |
|
Book Value (p.s.)
|
0.57 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-531.9 |
|
Return on Assets (ttm)
|
-23.5 |
|
Return on Equity (ttm)
|
-74.4 |
|
Qtrly Rev. Growth
|
-7 |
|
Gross Profit (p.s.)
|
-0.26 |
|
Sales Per Share
|
0.1 |
|
EBITDA (p.s.)
|
-0.58 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-50 (M) |
|
Levered Free Cash Flow
|
-28 (M) |
Stock Valuations |
|
PE Ratio
|
-1.4 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.35 |
|
Price to Sales
|
7.26 |
|
Price to Cash Flow
|
-1.51 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-05-29 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
